HPV阳性口咽癌年龄相关风险分层:对治疗降阶梯的启示
BACKGROUND: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC).…
要点
- 62岁为HPV阳性口咽癌OS的关键年龄阈值,<62岁者OS显著更优(HR 0.61)。
- 基于年龄与AJCC第八版分期的RPA模型可将患者分为五级风险组,2年OS从96.8%至47.5%。
- 极低危组(T0-2N0-1M0且<62岁)单纯放疗与放化疗OS无显著差异,或可考虑豁免同步化疗。
核心结论
- 基于AJCC第八版分期和年龄的风险分层模型可用于HPV阳性口咽癌,极低危组患者从同步化疗中获益有限,可考虑豁免。
主要发现
- 限制性立方样条分析显示62岁为重要临界阈值,多变量Cox分析显示<62岁患者OS显著改善(HR 0.61,95%CI 0.54-0.70,p<0.001)。
- RPA将患者分为五级风险组,2年OS分别为极低危96.8%、低危93.7%、中危86.1%、高危74.6%、极高危47.5%。
- 极低危组(T0-2N0-1M0且<62岁)中,单纯放疗与放化疗的OS无显著差异。
- 外部验证队列UHN(N=843)和NCC(N=167)提示极低危患者或可豁免同步化疗。
关键数值与推荐
- 年龄阈值62岁;极低危组定义为T0-2N0-1M0且年龄<62岁;风险分层基于AJCC第八版分期和年龄。
临床怎么用
- 对于T0-2N0-1M0且<62岁的HPV阳性口咽癌患者,可考虑豁免同步化疗,但需结合临床判断并参考未来降阶梯试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies. METHODS: Data were extracted from the SEER database (2018-2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV-positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS. RESULTS: Of the 10 283 eligible patients (87.9% male; median age, 62 years), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62 years of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62 years exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54-0.70; p < 0.001). RPA stratified patients into five risk groups with distinct 2-year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low-risk group (T0-2N0-1M0 and younger than 62 years), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN (N = 843) and NCC (N = 167) cohorts suggested that extremely low-risk patients might be spared concurrent chemotherapy. CONCLUSIONS: This study developed a risk stratification model for patients with p16-positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low-risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de-escalation trials.
引用
- Zhang C, Cheng Z, Jiang X, et al. Age-Related Risk Stratification in HPV-Positive Oropharyngeal Cancer: Implications for Treatment De-Intensification. Head Neck. 2026. PMID: 41525711. doi:10.1002/hed.70167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。